Conference
Abstract P3: Andexanet Alfa for Acute Bleeding During Treatment With Edoxaban
Abstract
Introduction: We previously reported results of a prospective cohort study evaluating andexanet alfa (andexanet) for anticoagulation reversal in patients with acute bleeding on a factor Xa inhibitor. Study enrollment continued to accumulate additional data on patients on edoxaban, which are presented here. Methods: Patients with acute major bleeding within 18 hours of edoxaban intake were prospectively enrolled. Patients received a 400 or 800 …
Authors
Benz AP; Xu L; Eikelboom JW; Middeldorp S; Milling TJ; Crowther M; Yue P; Conley P; Lu G; Connolly SJ
Volume
52
Publisher
Wolters Kluwer
Publication Date
March 2021
DOI
10.1161/str.52.suppl_1.p3
Conference proceedings
Stroke
Issue
Suppl_1
ISSN
0039-2499